Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CACabaletta Bio, Inc. logo

Cabaletta Bio, Inc. (CABA)

NASDAQ Global Select · Currency in USD
$1.47 ▼ -0.05 (-3.29%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.48 ▲ +0.01 (+0.68%)
After hours: Oct 23, 7:45 PM ET

Summary

Previous Close
$1.52
Open
$1.50
Day's Range
$1.40 – $1.50
52 Week Range
$1.39 – $4.23
Volume
3,991,476
Avg. Volume
5,224,623
Market Cap
$249.23M
Beta (5Y Monthly)
3.48
PE Ratio (TTM)
--
EPS (TTM)
-$1.20
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$16.33

Profile: Cabaletta Bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
156
CEO
Steven A. Nichtberger

Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.33 · Revenue est. $1.67M
DateEst.Actual
Aug 13, 2026-$0.37-$0.34Beat
May 14, 2026-$0.41-$0.39Beat
Mar 23, 2026-$0.45-$0.40Beat
Nov 10, 2025-$0.49-$0.44Beat
Aug 7, 2025-$0.71-$0.73Miss
May 15, 2025-$0.67-$0.71Miss

Analyst view

Consensus price target
$16.33 ▲ +1,010.9%
Range $3.00 – $32.00
Rating: Buy
Buy 83% · Hold 17% · Sell -0%

Get free alerts on CABA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.